Abstract | AIM: METHOD: A 25-question survey was distributed to members of the ALLG from December 2020 to July 2021. RESULTS: Sixty-four clinicians across Australia, New Zealand and Singapore responded. Clinicians treated a median of 15 MDS patients annually. Twenty-nine (45%) reported having institutional guidelines regarding prophylactic PLT-T. Although 60 (94%) said they would consider using TXA, most (58/64; 91%) did not have institutional guidelines. Clinical scenarios showed prophylactic PLT-T was more likely administered for patients on disease-modifying therapy (49/64; 76%, commonest threshold <10 × 109 /L) or with minor bleeding (32/64 [50%] transfusing at threshold <20 × 109 /L, 23/64 [35%] at <10 × 109 /L). For stable untreated patients, 29/64 (45%) would not give PLT-T and 32/64 (50%) would. Most respondents (46/64; 72%) were interested in participating in trials in this area. Potential barriers included resource limitations, funding and patient/clinician acceptance. CONCLUSION: Real-world management of MDS-related thrombocytopenia varies and there is a need for clinical trials to inform practice.
|
Authors | Allison Mo, Robert Weinkove, Erica M Wood, Jake Shortt, Anna Johnston, Zoe K McQuilten, Australasian Leukaemia and Lymphoma Group Supportive Care Scientific Working Party |
Journal | European journal of haematology
(Eur J Haematol)
Vol. 112
Issue 4
Pg. 621-626
(Apr 2024)
ISSN: 1600-0609 [Electronic] England |
PMID | 38123137
(Publication Type: Journal Article)
|
Copyright | © 2023 The Authors. European Journal of Haematology published by John Wiley & Sons Ltd. |
Chemical References |
|
Topics |
- Humans
- Tranexamic Acid
(therapeutic use)
- Platelet Transfusion
(adverse effects)
- Hemorrhage
(therapy, drug therapy)
- Thrombocytopenia
(therapy, drug therapy)
- Myelodysplastic Syndromes
(drug therapy)
|